MGI, a company with a global reputation in the field of gene sequencing, has recently made another big move. Their latest DNBSEQ-T7 sequencer has officially landed and started operation, which is undoubtedly a major refresh for the gene sequencing industry.
As MGI's latest flagship product, the DNBSEQ-T7 sequencer has significantly improved performance, speed, and accuracy. As soon as the instrument was launched in 2018, it attracted wide attention in the industry. Its high throughput makes it widely used in various gene sequencing scenarios such as whole-genome sequencing and ultra-deep exome sequencing.
Since its establishment, MGI has always adhered to customer demand-oriented, continuously strengthened product R&D and production, and carried out rapid iteration of products with technological innovation. They continue to strengthen the soundness of the product spectrum to meet the needs of customers in various application scenarios. This persistent pursuit of technology and products has enabled MGI to achieve important breakthroughs and leading positions in the field of gene sequencing.
This year, MGI upgraded the DNBSEQ-T7 sequencer to reduce the laser power per unit area by adding a spectroscopic system, thereby reducing the damage to samples and improving sequencing quality. This upgrade once again proves MGI's emphasis on technology research and development, as well as its determination to improve product performance and quality.
In addition, MGI's DNBSEQ-T7 sequencer was successfully implemented and put into operation in Kexin Medical Laboratory. Li Ying, Chairman of Kexin Medical Laboratory, said: "MGI's DNBSEQ-T7 sequencer will bring great convenience to our scientific research work, and its efficient and accurate performance will strongly promote our scientific research process. ”
It is understood that the DNBSEQ-T7 sequencer can complete the sequencing task within 24 hours, and the domestic single-cell platform is adapted to further accelerate the solution of the bottleneck problem of single-cell data production. This is great news for single-cell research. With the development of the life sciences, the demand for single-cell sequencing is increasing, and this feature of the DNBSEQ-T7 sequencer is expected to accelerate the research process in this field.
The successful launch and operation of MGI's DNBSEQ-T7 sequencer not only demonstrates MGI's leading position in gene sequencing technology, but also demonstrates China's research strength in the field of life sciences. In the future, it is reasonable to expect MGI to continue to lead the development of gene sequencing and make greater contributions to global life science research.